表皮生长因子受体抑制剂所致紫癜性药疹:32例临床病理研究
该前瞻性研究纳入32例使用EGFR抑制剂后出现紫癜性皮损的非小细胞肺癌患者,中位出现时间3.5个月,皮损以下肢紫癜性斑丘疹为主,56%伴脓疱,63%检出金黄色葡萄球菌。组织病理示表皮成熟不良、中性粒细胞外渗等,所有患者经至少1周全身抗生素治疗好转。
要点
- EGFR抑制剂相关紫癜性药疹中位出现时间3.5个月,以下肢紫癜性斑丘疹为主。
- 56%患者伴脓疱,63%检出金黄色葡萄球菌,常见于有脓疱者。
- 所有患者经至少1周全身抗生素治疗好转,44%调整了EGFR抑制剂剂量。
核心结论
- EGFR抑制剂所致紫癜性药疹不常见,但具有特征性临床与组织病理表现。
- 细菌病原体在该反应中的作用重要,需进一步探索。
研究设计与样本
- 前瞻性研究,纳入2013年1月1日至2015年12月31日期间在三级转诊医疗中心皮肤肿瘤联合门诊就诊的32例患者。
- 患者均为使用EGFR抑制剂后出现紫癜性皮损者。
主要发现
- 32例中14例无脓疱(平均[SD]年龄60[11]岁;12女2男),18例伴脓疱(平均[SD]年龄64[11]岁;12女6男)。
- 皮损中位出现时间3.5个月,主要表现为下肢紫癜性斑疹、丘疹和融合性斑块。
- 18例(56%)可见大小不等的脓疱,11例(34%)皮损累及下肢以外部位,13例(41%)出现湿疹样裂纹特征。
- 细菌病原体常见,以金黄色葡萄球菌最突出,20例(63%)检出,常见于有皮肤脓疱者。
- 组织病理主要特征为表皮成熟不良、中性粒细胞外渗、血管周围淋巴细胞和中性粒细胞浸润、红细胞外渗及内皮肿胀;皮损中丝聚蛋白和人β防御素2表达明显降低。
临床怎么用
- 对使用EGFR抑制剂后出现紫癜性皮损者,应评估脓疱和细菌感染,尤其金黄色葡萄球菌。
- 全身抗生素治疗至少1周可改善皮损,部分患者需调整EGFR抑制剂剂量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Purpuric skin lesions have only rarely been reported in patients receiving epidermal growth factor receptor inhibitors. However, their clinical and histopathologic presentations have varied considerably. OBJECTIVE: To characterize purpuric skin eruptions caused by epidermal growth factor receptor inhibitors. DESIGN, SETTING, AND PARTICIPANTS: This prospective study enrolled 32 patients who presented to an integrated dermato-oncologic clinic in a tertiary referral medical center with purpuric skin lesions after using epidermal growth factor receptor inhibitors from January 1, 2013, through December 31, 2015. EXPOSURES: Epidermal growth factor receptor tyrosine kinase inhibitors, including gefitinib, erlotinib, and afatinib. MAIN OUTCOMES AND MEASURES: Clinical presentations, histopathologic features, laboratory examinations, and treatment outcomes of patients with purpuric drug eruptions. RESULTS: Thirty-two patients, 14 with purpuric drug eruptions without pustules (mean [SD] age, 60 [11] years; 12 female and 2 male) and 18 with purpuric drug eruptions with pustules (mean [SD] age, 64 [11] years; 12 female and 6 male), were identified. The median time to development of skin lesions was 3.5 months. The clinical presentations were characterized by purpuric macules, papules, and confluent plaques predominantly on the lower extremities. Pustules in various sizes could be found in 18 patients (56%). Eleven patients (34%) had skin lesions that covered places other than the lower extremities. Eczema craquelé-like features developed in 13 patients (41%). Bacterial pathogens were frequently identified in these skin lesions. Among them, Staphylococcus aureus was the most predominant and was found in 20 patients (63%), commonly in those with cutaneous pustules. Epidermal dysmaturation, neutrophil exocytosis, perivascular infiltration of lymphocytes and neutrophils, red blood cell extravasation, and plumping endothelium were the main histopathologic features. The expressions of filaggrin and human β-defensin 2 in lesional skin of these patients were markedly reduced. All patients improved after receiving at least 1 week of systemic antibiotic treatment; the doses of epidermal growth factor receptor inhibitors were also changed for 14 patients (44%). CONCLUSIONS AND RELEVANCE: Purpuric drug eruptions caused by epidermal growth factor receptor inhibitors are uncommon and have characteristic clinical and histopathologic presentations. The role of bacterial pathogens in this reaction is important and requires further exploration.
引用
- Cho YT, Chen KL, Sheen YS, et al. Purpuric Drug Eruptions Caused by Epidermal Growth Factor Receptor Inhibitors for Non-Small Cell Lung Cancer: A Clinicopathologic Study of 32 Cases. JAMA Dermatol. 2017. PMID: 28538945. doi:10.1001/jamadermatol.2017.0903
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。